Mounjaro and Blood Clots: What Does the Evidence Show?

Does Mounjaro cause blood clots, according to clinical trials and UK guidance?

The short answer is: not according to current evidence. The SURMOUNT-1 trial, published in the New England Journal of Medicine, involved 2,539 adults over 72 weeks and reported Mounjaro's safety profile in detail. Venous thromboembolism was not identified as a treatment-related adverse event in that programme. The UK SmPC (the prescribing document that sets out every known risk) does not include blood clots among Mounjaro's listed side effects, and the NHS tirzepatide medicines page reflects the same picture.

The MHRA's Black Triangle designation means tirzepatide is subject to enhanced post-marketing surveillance. Prescribers and patients are encouraged to report any unexpected reactions via the Yellow Card scheme, and the regulator publishes Drug Safety Updates when emerging signals warrant them. No such update relating to clotting has been issued for tirzepatide. That is reassuring, though it is not a guarantee: pharmacovigilance is ongoing, and reporting unusual symptoms through the Yellow Card service remains worthwhile.

If you have seen claims online linking Mounjaro to clots, they most likely reflect general confusion with other medicines or with individual case reports that have not been confirmed as causal. For a fuller picture of what is actually monitored on treatment, our page on blood tests while taking Mounjaro explains which parameters prescribers typically track.

Why does obesity itself affect clot risk, and does weight loss change that?

This is where the question gets genuinely interesting. Obesity is a recognised, independent risk factor for deep vein thrombosis and pulmonary embolism. The mechanisms include raised levels of clotting factors, reduced physical activity, chronic low-grade inflammation, and increased intra-abdominal pressure. So people who are eligible for Mounjaro may already carry a modestly elevated baseline risk simply because of their weight, not because of the medicine.

Sustained weight loss generally improves cardiovascular risk markers. Reductions in inflammatory cytokines, improvements in lipid profiles, and lower blood pressure have all been documented alongside significant weight loss in the SURMOUNT programme. Whether these improvements translate directly into a measurable reduction in clot risk over the long term is still being studied, but the direction of travel in the data is favourable.

There is also a specific context worth raising: people with limited mobility (for example, those recovering from surgery or a long illness) face a temporarily higher clot risk regardless of weight. If you are on Mounjaro and you are due to have an operation, NHS England guidance is clear that your surgical team and anaesthetist need to know you are taking a GLP-1 medicine beforehand. Our clinical team page for our lead prescriber gives a sense of the clinical oversight built into how we review every patient.

Who should be especially careful, and what should you tell your prescriber?

If any of the following apply to you, raise them explicitly during your consultation, before treatment starts:

A personal history of DVT or pulmonary embolism, a known hereditary clotting disorder (such as Factor V Leiden or antiphospholipid syndrome), current anticoagulant therapy (warfarin, rivaroxaban, apixaban and similar), recent major surgery or prolonged immobility, or a family history of unexplained clotting events in younger relatives. None of these is an automatic bar to treatment, but each one is part of the clinical picture a prescriber needs to assess.

Separately, if you notice unexplained leg swelling, redness or pain in one leg, sudden breathlessness, or chest pain while on any medicine, seek urgent medical attention. These symptoms warrant same-day assessment regardless of what treatment you are on. Our page on blood in urine and Mounjaro covers another set of symptoms that sometimes prompt similar questions about vascular effects.

For broader context on how Mounjaro works and what the licensed treatment pathway involves, our tirzepatide overview covers the mechanism and clinical programme in full. Understanding what Mounjaro costs privately in the UK is also a common question once people have decided they want to explore treatment.

What about giving blood or having blood tests while on Mounjaro?

These are related questions that come up often. Donating blood while taking Mounjaro is addressed specifically on our guide to giving blood on Mounjaro, the short version is that current NHS Blood and Transplant guidance asks about medicines at the point of donation, and you should declare any prescription treatment.

Routine blood monitoring during Mounjaro treatment is common practice. Some prescribers check kidney and liver function, HbA1c, and lipid levels, particularly at baseline and after several months. Our Mounjaro blood tests page sets out which tests are typically relevant and why. None of these panels are specifically looking for clotting changes, but they build the broader picture of how your body is responding.

Some people also notice unexpected psychological shifts during treatment. That is a separate but legitimate area of interest covered on our page on the psychological effects of Mounjaro.

If you are considering starting treatment and want your full medical history reviewed by a clinician who will read it properly, speak to our prescribers through a free consultation, same working day, reviewed by a GPhC-registered Independent Prescriber, not a decision tree.